Financhill
Sell
20

GBIO Quote, Financials, Valuation and Earnings

Last price:
$5.24
Seasonality move :
-43.89%
Day range:
$5.09 - $5.36
52-week range:
$3.00 - $13.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.45x
P/B ratio:
0.69x
Volume:
27.7K
Avg. volume:
69.6K
1-year change:
-61.62%
Market cap:
$35M
Revenue:
$19.9M
EPS (TTM):
-$7.36

Analysts' Opinion

  • Consensus Rating
    Generation Bio Co. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $9.33, Generation Bio Co. has an estimated upside of 78.8% from its current price of $5.22.
  • Price Target Downside
    According to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $5.22.

Fair Value

  • According to the consensus of 5 analysts, Generation Bio Co. has 78.8% upside to fair value with a price target of $9.33 per share.

GBIO vs. S&P 500

  • Over the past 5 trading days, Generation Bio Co. has underperformed the S&P 500 by -1.63% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Generation Bio Co. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Generation Bio Co. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Generation Bio Co. reported revenues of $1.6M.

Earnings Growth

  • Generation Bio Co. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Generation Bio Co. reported earnings per share of -$0.82.
Enterprise value:
-28.6M
EV / Invested capital:
-0.37x
Price / LTM sales:
7.45x
EV / EBIT:
--
EV / Revenue:
-1.87x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.25x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$10.4M
Return On Assets:
-31.87%
Net Income Margin (TTM):
-410.13%
Return On Equity:
-84.94%
Return On Invested Capital:
-41.48%
Operating Margin:
-1348.68%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $3M $18.6M $15.3M $7.6M $1.6M
Gross Profit -$2.3M $13.5M $10.4M $6.4M $190K
Operating Income -$135.1M -$90.2M -$78.3M -$16.7M -$21.5M
EBITDA -$129.8M -$85.1M -$73.4M -$15.5M -$20.1M
Diluted EPS -$1.98 -$2.19 -$7.36 -$0.23 -$0.82
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $403.3M $310.6M $297.8M $191.3M $93.5M
Total Assets $464M $402.8M $381.5M $248.8M $121.9M
Current Liabilities $14.5M $17.3M $32.8M $30.2M $21M
Total Liabilities $56.8M $94.1M $149.6M $144.3M $71.3M
Total Equity $407.2M $308.7M $231.9M $104.4M $50.6M
Total Debt $46.7M $76.7M $71M $83M $19.7M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations -$50.8M -$97.8M -$113.7M -$19.5M -$52.7M
Cash From Investing -$26.2M $22.3M $113.7M $12.7M $25.5M
Cash From Financing $35.8M $183K $215K -$3K -$2K
Free Cash Flow -$54.3M -$104.4M -$114.7M -$19.6M -$52.7M
GBIO
Sector
Market Cap
$35M
$28.4M
Price % of 52-Week High
37.83%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
32.52%
-1.32%
1-Year Price Total Return
-61.62%
-22.19%
Beta (5-Year)
1.959
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $5.21
200-day SMA
Buy
Level $4.90
Bollinger Bands (100)
Sell
Level 4.85 - 6.31
Chaikin Money Flow
Buy
Level 2.5M
20-day SMA
Sell
Level $5.27
Relative Strength Index (RSI14)
Sell
Level 44.70
ADX Line
Sell
Level 17.09
Williams %R
Neutral
Level -59.7403
50-day SMA
Sell
Level $5.74
MACD (12, 26)
Sell
Level -0.14
25-day Aroon Oscillator
Sell
Level -24
On Balance Volume
Neutral
Level 15.3M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-4.1763)
Sell
CA Score (Annual)
Level (-1.7091)
Buy
Beneish M-Score (Annual)
Level (-2.5018)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.6723)
Buy
Piotroski F Score (Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Stock Forecast FAQ

In the current month, GBIO has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The GBIO average analyst price target in the past 3 months is $9.33.

  • Where Will Generation Bio Co. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Generation Bio Co. share price will rise to $9.33 per share over the next 12 months.

  • What Do Analysts Say About Generation Bio Co.?

    Analysts are divided on their view about Generation Bio Co. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Generation Bio Co. is a Sell and believe this share price will drop from its current level to $7.00.

  • What Is Generation Bio Co.'s Price Target?

    The price target for Generation Bio Co. over the next 1-year time period is forecast to be $9.33 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.

  • Is GBIO A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Generation Bio Co. is a Hold. 3 of 5 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of GBIO?

    You can purchase shares of Generation Bio Co. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Generation Bio Co. shares.

  • What Is The Generation Bio Co. Share Price Today?

    Generation Bio Co. was last trading at $5.24 per share. This represents the most recent stock quote for Generation Bio Co.. Yesterday, Generation Bio Co. closed at $5.22 per share.

  • How To Buy Generation Bio Co. Stock Online?

    In order to purchase Generation Bio Co. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

How High Could NVIDIA Stock Go?
How High Could NVIDIA Stock Go?

NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 62x

Buy
61
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 38x

Buy
63
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 40x

Alerts

Sell
44
PSTG alert for Dec 5

Pure Storage, Inc. [PSTG] is up 5.05% over the past day.

Sell
15
HOV alert for Dec 5

Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.

Buy
69
ASTS alert for Dec 5

AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock